Alpine Immune Sciences (ALPN)
(Delayed Data from NSDQ)
$64.56 USD
-0.06 (-0.09%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $64.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Alpine Immune Sciences, Inc. [ALPN]
Reports for Purchase
Showing records 1 - 20 ( 153 total )
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Call it ALPN Peak; VRTX to Acquire ALPN for $65/sh; D/G to Neutral
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Translational Data Boost Our Enthusiasm to See What Povetacicept Can Do For Lupus Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Oh the Places Povetacicept Can Go; New Translational Data at SLEuro
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
2023 Results; Povetacicept Program Revs Up With Multiple Upcoming Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Updated RUBY-3 Data at WCN; Increasing PT to $47
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
The Class Gets High Marks; Povetacicept Ahead of the Curve
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Povetacicept Remains Primary Focus as AbbVie Amends Acazicolcept Option Agreement; Price Target Upped to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Acazicolcept Study Cut Short; Sharpening Focus on Povetacicept Opportunities
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Could 2024 Finally Be Biotech''s Breakthrough Year?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for ALPN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Alpine Immune Sciences, Inc.
Industry: Medical - Drugs
3Q23 Results; Building on Recent Clinical Momentum
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J